MON-022 Enhancing Patient Care: Co-Creation and Validation of a New and Improved Delivery System for Lanreotide Depot/Autogel and Its Evaluation by US Healthcare Professionals

Lanreotide autogel/depot, a somatostatin analogue used to treat patients with acromegaly and gastroenteropancreatic neuroendocrine tumours (GEP-NETs), is currently supplied as a sterile, ready-to-use, single-dose prefilled syringe and is administered subcutaneously. To further enhance patient care,...

Descripción completa

Detalles Bibliográficos
Autores principales: Adelman, Daphne, Truong Thanh, Xuan-Mai, Megret, Clémentine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Healthcare Delivery and Education
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550760/
http://dx.doi.org/10.1210/js.2019-MON-022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550760/
http://dx.doi.org/10.1210/js.2019-MON-022

Ejemplares similares